M A Palmatier1, A M Kang, K K Kidd. 1. Department of Genetics, Yale University School of Medicine, Yale University, New Haven, CT 06520-8005, USA.
Abstract
BACKGROUND: Catechol-O-methyltransferase (COMT) has been investigated as a candidate gene in many neurologic disorders involving catecholaminergic systems. The NlaIII restriction site polymorphism (RSP) at COMT is a G<-->A (site absent<-->site present) single nucleotide polymorphism (SNP) at nucleotide 322/472 (in the short or long mRNA) that results in a Val<-->Met polymorphism at amino acid 108/158 (in soluble or membrane-bound) COMT protein and different enzyme activity levels, high for Val, low for Met. COMT enzyme activity is known to vary among ethnic groups, presumably as a result of different population frequencies of these COMT alleles. We have undertaken a direct survey of allele frequencies of this polymorphism in a global sample of populations. METHODS: We typed 1314 individuals from 30 different populations using PCR of the relevant region followed by digestion with NlaIII and electrophoresis. RESULTS: The frequencies of the low activity allele (COMT*L, NlaIII site-present) vary significantly from 0.01 to 0.62. Europeans have nearly equal frequencies of the two alleles while the COMT*H allele is much more common in populations in all other parts of the world. Sequencing in nonhuman primates indicates that COMT*H is the ancestral allele in humans. CONCLUSIONS: This is the first global survey of the COMT*L and COMT*H allele frequencies, confirming and extending earlier studies to show significant world-wide variation. This is also the first study establishing the COMT*L allele as the derived allele unique to humans. Henceforth, in any population-based association studies of this polymorphism, the control allele frequencies should be in agreement with these published values for corresponding ethnic groups.
BACKGROUND:Catechol-O-methyltransferase (COMT) has been investigated as a candidate gene in many neurologic disorders involving catecholaminergic systems. The NlaIII restriction site polymorphism (RSP) at COMT is a G<-->A (site absent<-->site present) single nucleotide polymorphism (SNP) at nucleotide 322/472 (in the short or long mRNA) that results in a Val<-->Met polymorphism at amino acid 108/158 (in soluble or membrane-bound) COMT protein and different enzyme activity levels, high for Val, low for Met. COMT enzyme activity is known to vary among ethnic groups, presumably as a result of different population frequencies of these COMT alleles. We have undertaken a direct survey of allele frequencies of this polymorphism in a global sample of populations. METHODS: We typed 1314 individuals from 30 different populations using PCR of the relevant region followed by digestion with NlaIII and electrophoresis. RESULTS: The frequencies of the low activity allele (COMT*L, NlaIII site-present) vary significantly from 0.01 to 0.62. Europeans have nearly equal frequencies of the two alleles while the COMT*H allele is much more common in populations in all other parts of the world. Sequencing in nonhuman primates indicates that COMT*H is the ancestral allele in humans. CONCLUSIONS: This is the first global survey of the COMT*L and COMT*H allele frequencies, confirming and extending earlier studies to show significant world-wide variation. This is also the first study establishing the COMT*L allele as the derived allele unique to humans. Henceforth, in any population-based association studies of this polymorphism, the control allele frequencies should be in agreement with these published values for corresponding ethnic groups.
Authors: A Meyer; D N Klein; D C Torpey; A J Kujawa; E P Hayden; H I Sheikh; S M Singh; G Hajcak Journal: Genes Brain Behav Date: 2012-06-28 Impact factor: 3.449
Authors: Warren D Taylor; Stephan Züchner; Martha E Payne; Denise F Messer; Tracy J Doty; James R MacFall; John L Beyer; K Ranga R Krishnan Journal: Psychiatry Res Date: 2007-05-23 Impact factor: 3.222
Authors: Lea K Krugel; Guido Biele; Peter N C Mohr; Shu-Chen Li; Hauke R Heekeren Journal: Proc Natl Acad Sci U S A Date: 2009-10-12 Impact factor: 11.205
Authors: M V Alfimova; V E Golimbet; I K Gritsenko; T V Lezheiko; L I Abramova; M A Strel'tsova; I V Khlopina; R Ebstein Journal: Neurosci Behav Physiol Date: 2007-09
Authors: Michele L Cote; Wonsuk Yoo; Angela S Wenzlaff; Geoffrey M Prysak; Susan K Santer; Gina B Claeys; Alison L Van Dyke; Susan J Land; Ann G Schwartz Journal: Carcinogenesis Date: 2009-01-27 Impact factor: 4.944
Authors: Hamed Samavat; Giske Ursin; Tim H Emory; Eunjung Lee; Renwei Wang; Carolyn J Torkelson; Allison M Dostal; Karen Swenson; Chap T Le; Chung S Yang; Mimi C Yu; Douglas Yee; Anna H Wu; Jian-Min Yuan; Mindy S Kurzer Journal: Cancer Prev Res (Phila) Date: 2017-09-13